Pfizer (NYSE:PFE) Posts Better-Than-Expected Sales In Q4
Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results , with sales up 21.9% year on year to $17.76 billion. On the other hand, the company’s full-year revenue guidance of $62.5 billion at the midpoint came in 0.
Pfizer exceeds Q4 earnings estimates as covid product sales outperform expectations
Strong Covid product sales and cost-cutting initiatives drove Pfizer's $17.76 billion in revenue in Q4, exceeding Wall Street's projections. The business also presented their financial projection for 2025.
Pfizer stock rises after beating Q4 expectations
Pfizer (NYSE: PFE) posted adjusted earnings per share of $0.63 for Q4, exceeding the analyst consensus of $0.48. Revenue came in at $17.8 billion, above expectations of $17.28 billion.
Pfizer Shares Rise on Better-Than-Expected 4Q
The positive quarter caps a busy year of cost cutting and pressure from an activist investor as Pfizer has sought to turn around company performance. Shares rose 1.2% to $26.51 soon after market open.
Pfizer tops earnings estimates as Covid product sales beat expectations and cost cuts pay off
The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its Covid business and stock price.
Pfizer Q4 Earnings Preview: Strong top line growth expected on COVID-19 product demand
Pfizer (NYSE:PFE) is scheduled to announce Q4 earnings results on Tuesday, February 4th, before market open. Analysts expect a profit of $0.46 per share (+360.0% Y/Y) on revenue of $17.26B (+21.1% Y/Y).
Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive Sales
Pfizer PFE reported fourth-quarter 2024 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate of 48 cents per share. The company had recorded earnings of 10 cents per share in the year-ago quarter.
Pfizer Rises on Q4 Earnings Beat, 2025 Outlook Reaffirmed
Pfizer beats Q4 estimates with 24.9% revenue growth, reaffirming 2025 guidance and targeting $4.5 billion in cost savings ...
Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down
Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...
Pfizer Q4 Results Beat Market; Confirms FY25 Outlook - Update
Drug major Pfizer Inc. (PFE), while reporting a profit in its fourth quarter, compared to prior year's loss, on Tuesday reaffirmed ...
Pfizer beats Q4, FY '24 earnings estimates, stock down slightly in premarket trading
Pfizer (PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...
Here’s Why Pfizer Inc. (PFE) Is Among the Best Dividend Stocks Under $30
Dividend stocks have remained a focal point for investors, especially amid market volatility and the growing need for steady ...
Pfizer (NYSE:PFE) Price Target Cut to $29.00 by Analysts at Citigroup
Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 ...
Pfizer (NYSE:PFE) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows ...
Armed robbery in Revesby18h
Pfizer's BRAFTOVI Regimen Boosts Survival in Phase 3 Trial
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...